Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INFU 
InfuSystems Holdings Inc (INFU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: INFU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.75
1 Year Target Price $13.75
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.98% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 194.66M USD | Price to earnings Ratio 39.71 | 1Y Target Price 13.75 |
Price to earnings Ratio 39.71 | 1Y Target Price 13.75 | ||
Volume (30-day avg) 4 | Beta 1.81 | 52 Weeks Range 4.61 - 9.97 | Updated Date 08/14/2025 |
52 Weeks Range 4.61 - 9.97 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 0.06 | Actual 0.12 |
Profitability
Profit Margin 3.63% | Operating Margin (TTM) 10.49% |
Management Effectiveness
Return on Assets (TTM) 6.73% | Return on Equity (TTM) 9.39% |
Valuation
Trailing PE 39.71 | Forward PE 44.44 | Enterprise Value 220103984 | Price to Sales(TTM) 1.39 |
Enterprise Value 220103984 | Price to Sales(TTM) 1.39 | ||
Enterprise Value to Revenue 1.57 | Enterprise Value to EBITDA 9.36 | Shares Outstanding 20426000 | Shares Floating 17718094 |
Shares Outstanding 20426000 | Shares Floating 17718094 | ||
Percent Insiders 6.65 | Percent Institutions 74.43 |
Upturn AI SWOT
InfuSystems Holdings Inc
Company Overview
History and Background
InfuSystems Holdings Inc. was founded in 1992 and provides infusion pumps and related services to oncology practices, infusion centers, and other healthcare providers. It focuses on delivering specialized medical equipment and related services.
Core Business Areas
- Infusion Services: Provides infusion pumps and related supplies for patients receiving therapies at home or in alternate sites of care. Services include pump maintenance, repair, and logistical support.
- Oncology: Provides infusion services, devices, and other services specifically for cancer treatment centers
Leadership and Structure
Richard DiIorio is the current CEO. The company has a typical corporate structure with executive leadership overseeing various departments such as operations, finance, and sales.
Top Products and Market Share
Key Offerings
- Infusion Pumps: Provides infusion pumps for delivering medications and fluids. Market share is estimated at 25% in the alternate site infusion market. Competitors include Option Care Health and BioScrip.
- Related Supplies and Services: Supplies, maintenance, and support services for infusion pumps. Market share information not readily available, highly competitive market with numerous logistical support companies
Market Dynamics
Industry Overview
The infusion therapy market is growing due to the increasing prevalence of chronic diseases and the shift towards home-based care. This market is driven by technological advances in infusion pumps and the need for cost-effective treatment options.
Positioning
InfuSystems is positioned as a provider of comprehensive infusion solutions, emphasizing its customer service and logistical capabilities. It competes with larger, more established players.
Total Addressable Market (TAM)
The global infusion therapy market is estimated at $20 billion. InfuSystems, with estimated revenues around 100 Million, holds a small but focused portion of the market, aiming to expand through specialized service offerings.
Upturn SWOT Analysis
Strengths
- Strong relationships with healthcare providers
- Focus on specialized infusion therapies
- Established logistical infrastructure
Weaknesses
- Smaller market share compared to larger competitors
- Dependence on a limited number of key customers
- Relatively high debt level
Opportunities
- Expanding into new geographic markets
- Acquiring smaller infusion service providers
- Developing innovative infusion pump technologies
Threats
- Increasing competition from larger players
- Changes in healthcare regulations
- Technological obsolescence
Competitors and Market Share
Key Competitors
- OPCH
- BIOS
Competitive Landscape
InfuSystems has strengths in its specialized offerings and customer service, but it faces strong competition from larger companies with greater resources and brand recognition.
Major Acquisitions
Amber Enterprises, Inc.
- Year: 2021
- Acquisition Price (USD millions): 52.5
- Strategic Rationale: Expanded InfuSystem's geographic reach and strengthened its oncology infusion services.
Growth Trajectory and Initiatives
Historical Growth: Growth has been moderate, driven by acquisitions and organic expansion. Performance varies depending on the segments.
Future Projections: Analysts predict continued revenue growth in the mid-single digits, with potential for margin expansion. Earnings growth is expected to recover as business matures.
Recent Initiatives: Recent initiatives include expanding its oncology infusion service offerings and optimizing its supply chain.
Summary
InfuSystems is a smaller player in the infusion services market with strengths in specialized areas. It has demonstrated moderate growth but faces challenges regarding profitability and competition. Future success depends on its ability to innovate and expand its market share, however its leverage on the balance sheet will limit its ability to acquire companies. Careful management of finances is important for the company's growth and success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Presentations
- Analyst Reports
- Company Press Releases
- Third Party Market Reports
- Financial Data Providers
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data and analysis are subject to change and may not be entirely accurate. Past performance is not indicative of future results. This analysis relies on publicly available information and may not reflect all factors relevant to an investment decision.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InfuSystems Holdings Inc
Exchange NYSE MKT | Headquaters Rochester Hills, MI, United States | ||
IPO Launch date 2007-12-27 | President, CEO & Director Ms. Carrie A. Lachance B.S.N., M.B.A., R.N. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 502 | Website https://www.infusystem.com |
Full time employees 502 | Website https://www.infusystem.com | ||
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates in two segments, Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.